Tepotinib price

The U.S. Food and Drug Administration (FDA) approvedtepotinib (tepotinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who carry mesenchymal epithelial transition (MET) exon 14 skipping alterations. Efficacy was demonstrated in the VISION trial, a multicenter, nonrandomized, open-label, multi-short-term study of 152 patients with advanced or metastatic NSCLC and MET exon 14 skipping alterations. Patients received tepotinib 450 mg orally once daily until disease progression or unacceptable toxicity.

The primary efficacy outcome measures were confirmed overall response rate (ORR) and duration of response. Among 69 treatment-naïve patients, the ORR was 43% and the median duration of response was 10.8 months. Among 83 previously treated patients, the ORR was 43% and the median duration of response was 11.1 months. The most common adverse reactions (≥20% of patients) were edema, fatigue, nausea, diarrhea, musculoskeletal pain, and dyspnea. Tepotinib can also cause interstitial lung disease, hepatotoxicity, and embryo-fetal toxicity.

The original drug of Tepotinib is a new type of drug that is not yet on the market in China and therefore has not been included in the medical insurance. The price of Tepotinib original drug specifications225mg*30 tablets per box listed overseas is around RMB 80,000 (the price may fluctuate due to the exchange rate). It has been on the market for a short time and is expensive. There are also Tepotinib generic drugs produced in other countries. The price of 225mg*60 tablets produced by a Lao pharmaceutical factory is around RMB 8,600 per box (the price may fluctuate due to the exchange rate). The ingredients of generic drugs produced abroad are basically the same as those of the original drug. For specific prices and drug details, please consult Yaode Medical Consultant.